Publication: NOVEL GEMCITABINE – RE(I) TRICARBONYL COMPLEXES COMBINATIONS, CONJUGATE AND FORMULATIONS WITH LIQUID CRYSTALLINE NANOPARTICLES FOR PANCREATIC CANCER PHOTODYNAMIC THERAPY
Date
2021
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
International Medical University
Abstract
With less than 10% of the 5-year survival rate, pancreatic ductal adenocarcinoma (PDAC) is known to be one of the most lethal types of cancer. Current literature supports that gemcitabine is the first-line treatment of PDAC. However, its poor cellular penetration, acquired and intrinsic chemoresistance is common despite the broad usage of gemcitabine. Photodynamic therapy (PDT), a more selective and minimally invasive treatment, may be used synergistically with gemcitabine to reduce the doses utilised and dose-related side effects. The anti-pancreatic cancer evaluation of gemcitabine and rhenium(I), Re(I) pyta complex as a single agent does not show much difference between with/without PDT treatment. In contrast, Re(I) bisquinolinyl complex was to the PDAC (SW1990 and BxPC3) at light irradiation regimen of 365 nm for 2.5 minutes and 1.3 J/cm2 (IC50 without PDT: > 100 μM; IC50 with PDT for BxPC3: 42.06 μM; IC50 with PDT for SW1990: 61.75 μM). Combinatorial therapy with gemcitabine and either Re(I) pyta complex or Re(I) bisquinolinyl complex was then performed. All the tested combinations indicated synergism at most ratios and no significant difference in synergism was observed between with/without PDT. To improve the cytotoxicity of Re(I) pyta complex, it was conjugated with gemcitabine and successfully killed PDAC. With the aim to enhance cellular uptake and therapeutic efficiency, potent Re(I) bisquinolinyl complex and gemcitabine were encapsulated into liquid crystalline nanoparticles (LCNPs) system. All LCNPs formulations were found to be homogeneous, with both drugs encapsulated efficiently, in nano-sized (159 to 173 nm) and stable within the acceptable range of zeta potential (+1.06 to -10 mV). Around 70% of gemcitabine and 90% of Re(I) bisquinolinyl complex were found to be entrapped efficiently in the synthesised LCNPs. The release rate of gemcitabine or/and Re(I) bisquinolinyl complex loaded into LCNPs were evaluated in vitro and the much hydrophilic gemcitabine was released at a faster rate than the much lipophilic Re(I) complex. LCNPs loaded with gemcitabine and Re(I) bisquinolinyl complex in 1:1 ratio illustrated the best anti-pancreatic cancer activity among the synthesised LCNPs formulations (IC50 of BxPC3: 0.15 μM; IC50 of SW1990: 0.76 μM) through apoptosis. This work highlights the relevance of drug combinations, drug conjugation and formulations with LCNPs strategies to improve therapeutic potency. Future in vivo validations will be helpful to further bridge this work from bench to bedside.
Description
Keywords
Immunosuppressive Agents, Adenocarcinoma, Pancreatic Neoplasms, Photochemotherapy, Liquid Crystals, Nanoparticles